NCT01580735View on ClinicalTrials.gov

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

ARQ 197

"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"

Trial Locations (1)

Unknown

Arakawa-ku

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT01580735 - ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer | Biotech Hunter | Biotech Hunter